Lv2
140 积分 2025-05-27 加入
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
21小时前
待确认
Discovery of MK-1088 as a Potent A2A/A2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy
21天前
已完结
Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual Inhibitor
27天前
已完结
Rh(III)-Catalyzed Imidoyl C–H Carbamylation and Cyclization to Bicyclic [1,3,5]Triazinones
1个月前
已完结
Optimization of METTL3 Inhibitors for the Treatment of Solid Tumors and AML
1个月前
已完结
Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors
2个月前
已完结
Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer
2个月前
已完结
Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy
2个月前
已完结
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma
3个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
3个月前
已完结
皖公网安备34019202002308
